Long-term efficacy of imatinib for treatment of metastatic GIST

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 277-286

  Patel, Shreyaskumar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gastrointestinal stromal tumor (GIST); Imatinib; KIT; Metastatic; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXON; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LOW DRUG DOSE; METASTASIS POTENTIAL; MUSCULOSKELETAL PAIN; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM METASTASIS; PATIENT COMPLIANCE; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84880916984     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2135-8     Document Type: Review

References (43)

1. Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1-S29
2. Ducimetiere F, Lurkin A, Ranchere-Vince D et al (2011) Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 6:Abstract e20294
3. Perez EA, Livingstone AS, Franceschi D et al (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202:623-629
4. Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103:821-829 (Pubitemid 40216412)
5. Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30:1213-1220 (Pubitemid 29480891)
6. Joensuu H, Fletcher C, Dimitrijevic S et al (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655-664 (Pubitemid 35314908)
7. Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557-586 (Pubitemid 351488293)
8. Medeiros F, Corless CL, Duensing A et al (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28:889-894 (Pubitemid 38856844)
9. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710 (Pubitemid 36159485)
10. Trent JC, Benjamin RS (2006) New developments in gastrointestinal stromal tumor. Curr Opin Oncol 18:386-395 (Pubitemid 44297252)
11. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825 (Pubitemid 41095223)
12. Tornillo L, Terracciano LM (2006) An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59:557-563 (Pubitemid 43886037)
13. Day E, Waters B, Spiegel K et al (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599:44-53
14. Savage DG, Antman KH (2002) Imatinib mesylate - a new oral targeted therapy. N Engl J Med 346:683-693 (Pubitemid 34815874)
15. Novartis Pharmaceuticals Corporation (2009) Gleevec/Glivec prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec-tabs.pdf. Accessed 30 Jan 2013
16. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056 (Pubitemid 32267975)
17. Rossi S, Miceli R, Messerini L et al (2011) Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 35:1646-1656
18. Casali PG, Blay JY (2010) Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v98-v102
19. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(suppl 2):S1-S41
20. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 (Pubitemid 34879334)
21. Green S, Weiss GR (1992) Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253 (Pubitemid 23008970)
22. Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625 (Pubitemid 351264357)
23. von Mehren M, Heinrich MC, Joensuu H et al (2011) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal tumors (GIST). J Clin Oncol 29:Abstract 10016
24. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632 (Pubitemid 351264358)
25. Blanke CD, Rankin C, Benjamin R et al (2011) Long-term survival on S0033 - a phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GISTs). Eur J Cancer 47(suppl 1):Abstract 9404
26. Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107-1113 (Pubitemid 46596763)
27. Le Cesne A, Ray-Coquard I, Bui BN et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942-949
28. Ray-Coquard IL, Bin Bui N, Adenis A et al (2010) Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study. J Clin Oncol (Meeting Abstracts) 28:Abstract 10032
29. Bertucci F, Ray-Coquard I, Bui Nguyen B et al (2012) Effect of five years of imatinib on cure for patients with advanced GIST: updated survival results from the prospective randomized Phase III BFR14 trial. J Clin Oncol 30:Abstract 10095
30. Domont J, Blay J, Ray-Coquard IL et al (2011) Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Result of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol 29:Abstract 10054
31. Perol D, Ray-Coquard I, Bui Nguyen B et al (2012) Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): results from the BFR14 phase III trial of the French Sarcoma Group. J Clin Oncol 30:Abstract 10092
32. Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757 (Pubitemid 41132637)
33. Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141-3147
34. Yoo C, Ryu MH, Kang BW et al (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28:1554-1559
35. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349 (Pubitemid 46621810)
36. Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689-695 (Pubitemid 38326618)
37. Blesius A, Cassier PA, Ray-Coquard IL et al (2011) Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol 29:Abstract 10048
38. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247-1253
39. Joensuu H, Trent JC, Reichardt P (2011) Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 37:75-88
40. Le Cesne A, Ray-Coquard IL, Bui Nguyen B et al (2011) Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. J Clin Oncol 29:Abstract 10015
41. Halpern R, Barghout V, Zarotsky V, Williams DE (2009) Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 16:215-223
42. Noens L, Van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401-5411
43. Mazzeo F, Duck L, Joosens E et al (2011) Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 31:1407-1409